Unveiling the Potential Drug Target and Biomarker CCDC172: A Coiled-Coil Domain-Containing Protein

Target Name: CCDC172

NCBI ID: G374355

CCDC172

Unveiling the Potential Drug Target and Biomarker CCDC172: A Coiled-Coil Domain-Containing Protein

Introduction

Proteins play a crucial role in the functioning of living organisms, and their abnormalities can lead to various diseases. One such protein, CCDC172 (coiled-coil domain-containing protein 172), has been identified as a potential drug target and biomarker. This protein is of great interest due to its unique structure, which allows it to interact with various signaling pathways. In this article, we will delve into the molecular mechanisms of CCDC172, its potential drug targets, and its role as a biomarker in various diseases.

Molecular Mechanisms of CCDC172

The CCDC172 protein is a member of the evolutionarily unrelated superfamily of transmembrane proteins, which includes proteins involved in various signaling pathways. CCDC172 is characterized by a unique structure, including a long coiled-coil domain and a short cytoplasmic tail.

The coiled-coil domain is a well-known structural feature that gives CCDC172 its unique physical properties. This domain is responsible for the protein's ability to form a stable, highly ordered structure when it is in solution. The coiled-coil domain also plays a critical role in the protein's stability and can interact with various signaling pathways.

CDC172 has multiple potential drug targets due to its unique structure and various signaling pathways. One of the most promising targets is the protein kinase B, which is known to play a critical role in various cellular signaling pathways. CCDC172 has been shown to interact with the protein kinase B, leading to the formation of a complex that enhances the activity of the protein. This interaction between CCDC172 and the protein kinase B makes it a promising target for drug development.

Another potential drug target for CCDC172 is the serine/threonine protein kinase P120, which is involved in various cellular signaling pathways, including cell growth, differentiation, and survival. CCDC172 has been shown to interact with P120, leading to the formation of a complex that enhances the activity of the protein. This interaction between CCDC172 and P120 makes it a promising target for drug development.

CDC172 has also been shown to interact with the protein tyrosine phosphatase (PTP) family, which is involved in various cellular signaling pathways, including cell growth, differentiation, and apoptosis. CCDC172 has also been shown to interact with the PTP3A protein, leading to the formation of a complex that enhances the activity of the protein. This interaction between CCDC172 and PTP3A makes it a promising target for drug development.

Potential Biomarkers for CCDC172

CDC172 has the potential to serve as a biomarker for various diseases due to its unique structure and various signaling pathways. One of the most promising biomarkers for CCDC172 is its ability to interact with various signaling pathways, including those involved in cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the most promising biomarkers for CCDC172 is its ability to interact with the protein PDGF-尾, which is involved in various signaling pathways, including cell growth, differentiation, and cancer. CCDC172 has been shown to interact with PDGF-尾, leading to the formation of a complex that enhances the activity of the protein. This interaction between CCDC172 and PDGF-尾 makes it a promising biomarker for cancer.

Another promising biomarker for

Protein Name: Coiled-coil Domain Containing 172

The "CCDC172 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC172 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets